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WATSON, S. J., H. AKIL AND J. M. WALKER. Anatomical and biochemical studies of the opioid peptides and related 
substances in the brain. PEPTIDES l: Suppl. 1, 11-20, 1980.--It is now clear that there are at least four opioid peptide- 
neuronal systems in mammalian brain: the enkephalins, beta-endorphin and dynorphin. The focus of this presentation will 
be twofold--to focus on the multiple transmitter problem as typified by the beta-END/alpha-MSH arcuate neuronal 
system, and to describe the newly-discovered dynorphin neuronal system. The beta-END/alpha-MSH neurons have been 
studied using antisera directed against different portions of the 31K precursor (ACTH/beta-LPH/beta-END). Although 
ACTH can be detected in brain, the final products of the brain 31K system seem to be beta-END and alpha-MSH (similar to 
the intermediate lobe of pituitary). It is emphasized that "normally" these neurons would appear to release two neuronally 
active substances. Recently, a second set of alpha-MSH immunoreactive neurons was discovered in rat brain. These 
neurons are not immunoreactive for any other part of the 31K precursor and are distributed quite differently than the 
arcuate beta-END/alpha-MSH cell group. Dynorphin is another major class of opioid peptide. It has been studied and found 
in magnocellular neurons and posterior pituitary. The relations between dynorphin and leu-enkephalin cells continues to be 
unclear. 
Opiate peptides /3-Endorphin Dynorphin ACTH a-MSH Immunocytochemistry Anatomy 
THE following chapter will present an overview of 
anatomical and physiological information regarding the sev- 
eral opiate peptides discovered to date---beta-endorphin, 
methionine enkephalin, leucine enkephalin and dynorphin. 
Each of these peptides appears to be contained in its own 
neuronal system. At the same time they seem to be related in 
one fashion or another to other neurotransmitter and specif- 
ically other peptide systems. The perspective of this chapter 
will be to highlight the characteristics of these opioid peptide 
systems with particular attention being paid to problems, 
tools, and novel or unusual perspectives. The primary in- 
formation from which most of these observations are drawn 
are the basic immunocytochemical and anatomical studies 
carried out by several laboratories including our own. Addi- 
tionally, other classes of information will be brought into the 
discussion as they are relevant to understanding the com- 
plexities of the system. For example, in the beta endorphin 
system we will present some biochemical, pharmacological 
and behavioral studies. This convergence of studies has 
proven to be a powerful tool for elucidating the function of 
this system in brain. 
The Beta-Endorphin/ACTH/Alpha-MSH/Gamma-MSH 
System 
The first study on the system involving beta-lipotropin 
was carried out by Moon and co-workers in the early '70's 
[29]. In that study it was shown that beta-lipotropin was 
distributed in pituitary in a fashion very similar to ACTH and 
alpha-MSH. That is, beta-lipotropin was stored in all of the 
cells of the intermediate lobe as well as the corticotrophs of 
the anterior lobe. With the discovery of beta-endorphin [9, 
17, 26] and the development of antisera against it, it was 
possible to confirm that ACTH, beta-endorphin and beta- 
lipotropin were stored in precisely the same locations in pi- 
tuitary [7,36]. Soon thereafter immunocytochemical studies 
of lipotropin and endorphin were extended to brain with the 
discovery of a separate and unique neuronal pool in central 
nervous system which contained both beta endorphin and 
beta lipotropin [6, 8, 52, 54, 57]. These neurons are located in 
the region of the arcuate nucleus of hypothalamus and con- 
tain fiber systems which project widely throughout the brain 
stem. The association of lipotropin and endorphin with 
ACTH and a-MSH in two pituitary cell groups strongly 
suggested the likelihood that there might be ACTH im- 
munoreactivity in brain also related to lipotropin and 
endorphin. 
Subsequently we [55] and others [22] carried out studies 
of ACTH immunoreactivity in central nervous system. We 
were able to locate it in precisely the same cells which con- 
tain beta-endorphin and beta-lipotropin [52]. These im- 
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FIG. 1. B-END cells (arrow) in the extreme posterior arcuate nucleus. Star is in the third ventricle, x300. 
munocytochemical studies were carried out after the elegant 
studies of Mains and Eipper [28], and Roberts and Herbert  
[39] in which they demonstrated the presence of a single 
major protein precursor molecule for ACTH, beta-endorphin 
and beta-lipotropin. Thus the theoretical linkage between 
endorphins, lipotropin and ACTH was strongly reinforced 
by the discovery of a common precursor molecule in 
pituitary. This molecule was shown to contain beta-lipotropin 
and beta-endorphin at the C terminus, ACTH in the mid portion 
of  the molecule and a fragment at the N terminus of unknown 
structure or function (called the 16K portion) [28]. The 
31,000 Dalton precursor molecule has since come to be 
known as either the 31K precursor,  pro-opiocortin or pro- 
opiomelanocortin. This elegant protein biochemical work on 
the 31K precursor [28,39] has been confirmed and expanded 
by the work of Nakanishi and coworkers [30] using molecu- 
lar biological tools. These workers determined the cDNA 
sequence from the pro-opiocortin messenger RNA suggest- 
ing a structure which, in every important aspect,  is identical 
to the sequence obtained from biochemical studies. They 
further revealed the amino acid composition and sequence of 
the 16K structure, gamma-MSH and of the signal peptide. 
Upon more careful evaluation of the distribution of the 
31K precursor and its products in pituitary, it was deter- 
mined that the two lobes of pituitary treated the 31K precur- 
sor in a different fashion [12,15]. The anterior lobe cells 
which produced ACTH were found to process pro- 
opiocortin into full ACTH with a modest  amount of beta- 
endorphin and a larger amount of beta-lipotropin. In con- 
trast, intermediate lobe cells carried the cleavage one step 
further. ACTH was cleaved into alpha-MSH (N-acetyl 
ACTH 1-13 amide) and CLIP (corticotropin-like intermedi- 
ate lobe peptide); whereas beta-lipotropin was very rapidly 
and almost completely cleaved into gamma-lipotropin and 
beta-endorphin. Thus the pituitary appeared to use the same 
general precursor information to make two different sets of  
products. The question remained as to whether brain acted 
more like anterior lobe or intermediate lobe. In subsequent 
studies using specific ACTH antisera and a serial section 
analysis we and others determined that the same cells in 
brain did produce ACTH, beta-lipotropin and fl-endorphin 
[4, 31, 52]. However,  since most of  the ACTH antibodies 
used in these studies could also bind to c~-MSH or CLIP, the 
question of which peptide was being studied had to be inves- 
tigated. Other groups had used specific a -MSH antisera and 
shown its presence in the CNS [32, 35, 46]. We extended 
these studies to show that all of the alpha-MSH positive cells 
in the arcuate nucleus produced beta endorphin as well 
[49,50]. Thus, it became clear that there was a very similar 
precursor-product system in brain and pituitary. That is, 
brain contains most of the protein pieces that one would 
expect for cleavage from the 31K precursor and that these 
pieces were stored within the same cells. With the develop- 
ment of antisera against the 16K portion of the 31K precur- 
sor and gamma-MSH it has been possible to reinforce this 
finding by demonstrating its existence in the beta-END con- 
taining neurons and pituitary cells [5,34]. 
As an interesting aside, while studying central nervous 
system distribution of alpha-MSH, a second set of cells with 
alpha-MSH immunoreactivity has been discovered [49,50]. 
This cell group is completely outside of arcuate nucleus but 
is still located in hypothalamus. It stretches from the top of 
the third ventricle in a dorsal lateral fashion out to the 
posterior regions of the hypothalamus ending with a sub- 
group abutting against the lateral hypothalamic sulcus. This 
set of  alpha-MSH positive cells is not positive for beta- 
endorphin, the C terminal of ACTH, gamma-lipotropin or 
16K, suggesting that the neurons contain an alpha-MSH-like 
peptide but do not seem to store other portions of the 31K 
molecule. 
In looking back over the 31K beta-endorphin/ACTH/ 
MSH system it becomes clear that there is an enor- 
ANATOMY AND BIOCHEMISTRY OF THE OPIOID PEPTIDES 13 
FIG. 2. a-MSH cells in the arcuate nucleus, x540. 
FIG. 3. a-MSH cells (arrows) near the fomix (star). These cells are not part of the arcuate B-END system. They 
only stain with a-MSH antisera, x250. 
mous complexity inherent in the biology of this precursor 
molecule. It is not only found in three different cell regions 
(anterior lobe and intermediate lobe of pituitary as well as 
arcuate nucleus of hypothalamus), but it produces several 
potentially active biological products within the same cell. 
Whether these substance would all qualify as active neuro- 
transmitters requires studies of their release, receptors,  
physiological and behavioral effects. Only a few studies have 
begun to address such issues. We shall focus here on work 
from our laboratory, which is beginning to shed light on the 
function of the brain 31K system. Our studies in human pain 
patients' have strongly suggested that endorphin and alpha- 
MSH can be released into the CSF by electrical stimulation 
of  periventricular sites known to produce relief of intractable 
pain [2, 3, 37, 38]. Similar studies by Hosobuchi and col- 
laborators [ 18] have shown the release of N terminal portions 
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FIG. 4. ct-MSH cells (arrows) in the lateral hypothalamus near the optic tract (star). These cells do not stain for 
/3-END. × 175. 
FIG. 5.16K positive cells in the arcuate nucleus. These same cells are positive for all other 31K antisera, x 155. 
of 31K (16K). The net effect of these release studies appears 
to argue that in humans, at least, major portions of this brain 
peptide system are electrically releaseable and would 
theoretically be biologically active. 
A number of  opiate receptor studies using specifically 
labelled beta-endorphin have demonstrated high affinity 
binding sites in central nervous system [1, 20, 24]. Such 
studies, along with others using beta-endorphin as a com- 
petitive inhibitor against other opiate ligands, suggest that 
beta-endorphin binds to both the delta receptor (which is 
selective for enkephalin) and the mu receptors (selective for 
morphine) [10,27]. More detailed studies (currently under- 
ANATOMY AND BIOCHEMISTRY OF THE OPIOID PEPTIDES 15 
~C 
- , r  
y o u  
L A ~  
tat1[ 
,k 
V ~  C T V  
FIG. 6. Schematic in coronal section through rat hypothalamus. The stars within the medial- 
inferior line with the notation "b.a" indicate arcuate 31K cells (c~-MSH,/3-END, 16K, etc). The 
open circles above the line "a"  indicate the cells staining for a-MSH only. Adapted from Konig 
and Klippel's atlas. 
way) are necessary to determine whether beta-endorphin 
labels a subpopulation of opiate receptors unique to this 
opiate peptide (Hewlett,  Akil, Barchas, and Li). 
There have been relatively fewer studies of alpha-MSH 
and gamma-MSH or ACTH in receptors in central nervous 
system. To date these studies have been extremely difficult. 
Our experience with them (in collaboration with J. 
Ramachandran, U.C.S.F.)  has revealed the existence of 
saturable binding of labelled ACTH and alpha-MSH to cen- 
tral nervous system membranes. However ,  the results are 
variable from experiment to experiment possibly due to the 
great hydrophobic nature of these peptides. Our results gen- 
erally suggest the existence of a small number of ACTH and 
alpha-MSH binding sites, which are differentially distributed 
across limbic structures. 
If one shifts to microinjection of ACTH, alpha-MSH, 
gamma-MSH and evaluates the effects of the pharmacologi- 
cal administration of these peptides a most interesting prob- 
lem emerges. As is well known the administration of opiates 
and opiate peptides can produce a narcotic specific analgesia 
when injected into the central gray area of rats (cf [47]). 
Using the same paradigm it has been possible to demonstrate 
that ACTH, alpha-MSH, des-acetyl-alpha-MSH and Orga- 
non 2766 (an active analog of  MSH) all produce a potent 
analgesia [47]. The rank ordering places the degradation re- 
sistant Organon analog at the top of the list with alpha-MSH 
being least potent. The Org 2766 compound is as potent as 
morphine in producing an analgesia. It should be noted that 
this analgesia is not cross tolerant with morphine nor is it 
blockable by naloxone. It would appear from these studies 
that not only is analgesia produced by the opiate portion of 
the 31K molecule, but that other portions of that same 
molecule appear to be capable of producing a significant 
biological action in the same direction (a non-opiate 
analgesia). Of further interest is the fact that the 
MSH/ACTH analgesia is most potent in the region of the 
beta endorphin bundle (and 31K product receptors). The net 
effect of  these studies is to suggest that the 31K molecule is 
designed to produce a set of  actions---some of which are 
opiate mediated, some not, but all of which are in the same 
physiological directions. Thus one would expect  an opiate 
analgesia as well as a non-opiate analgesia acting in concert. 
But what of the newly discovered gamma-MSH [30]? Does it 
produce an opiate-like or non-opiate-like analgesia? Does it 
have any actions at all? When injected in approximately 
equal molar amounts gamma-MSH 1-12 does not appear to 
produce an ACTH, alpha-MSH or Org 2766-1ike analgesia. 
In fact no obvious effect can be seen for the administration of 
this agent. However,  when it is administered in concert with 
ACTH, gamma-MSH is found to substantially potentiate the 
peak analgesia obtained from ACTH. It is as though the role 
of gamma-MSH is to provide another action which poten- 
tiates that of ACTH. This same sort of gamma-MSH/ACTH 
potentiation has been observed by others in the production 
of steroids from adrenal cells [33]. While these data are pre- 
liminary and in some ways difficult to interpret, perhaps the 
most reasonable suggestion would be that the net effect on 
the post-synaptic element of  all the 31K products (beta- 
endorphin, alpha-MSH or ACTH and gamma-MSH) would 
be a very powerful addition or synergism produced by a 
variety of  mechanisms. On the other hand, ACTH and 
beta-END have been suggested to be mixed against/an- 
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FIG. 7. A large group of dynorphin positive cells in the supraoptic nucleus (star in the optic tract). This is a 50 
/zm thick section. × 540. 
FIG. 8. Dynorphin positive processes in the posterior pituitary lobe (star), but not in the anterior (one arrow) or 
intermediate lobe (two arrows), x300. 
tagonist in other paradigms. Thus, the specific interactions 
and regulation of multiple substances deriving from pro- 
opiocortin proves to be new areas for research. 
The Enkephalins and Dynorphin: 
Related Substances or Not? 
The enkephalins were the first opiate peptides discovered 
[21] and in many ways have been much better studied than 
the beta-endorphin system. However, much less information 
is known about certain aspects of the enkephalins. For 
example, relatively little is known about the specific distri- 
bution of methionine versus leucine enkephalin, or the 
biosynthesis of enkephalins. In contrast a great deal is 
known about their structure activity relationships, their re- 
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FIG. 9. Dynorphin positive axon (arrows) in the ventromedial hypothalamic nucleus. ×2100. 
ceptors and their pharmacology. There are few obvious facts 
relevant to this paper. 
The enkephalins have been found to be separate from 
beta-endorphin [6,52] even though methionine-enkephalin 
shares a common sequence portion with the N terminus of 
beta-endorphin [21]. The distribution of the enkephalins 
(both methionine- and leucine-enkephalins) has been widely 
studied in rodent central nervous system [11, 13, 19, 41, 44, 
45, 48, 53]. A large number of cell groups has been dis- 
covered, scattered from rostral limbic structures to spinal 
cord (not to mention adrenal, peripheral nerves and ganglia) 
[42,43]. The enkephalin systems are thus extremely wide- 
spread, having extensive fiber distributions locally and in 
some cases, projecting along well defined pathways to 
neighboring structures, as in the case of the pallido-striatal 
enkephalin pathway [11]. Their anatomy suggests that 
enkephalins are well situated for major involvement in most 
of the functions classically associated with opiate action, 
such as respiration, temperature or pain control. A signifi- 
cant question relating to the distribution of methionine- and 
leucine-enkephalin revolves around whether they were in the 
same or different cells. Recent evidence by Larsson and 
co-workers [23] tends to strongly suggest that methionine- 
and leucine-enkephalin in every system studied to date are in 
fact separable systems. While the distribution of these two 
systems is extremely similar in the gross anatomical sense, 
careful study with properly prepared antisera allows one to 
see differences between the distribution of  methionine- and 
leucine-enkephalin cells. Thus it is possible to raise questions 
about separate physiological function and even separate re- 
ceptors. The question of  multiple receptors is extremely 
complicated, as many opiate alkaloids and peptides are 
rather '+indiscriminant" in the subtype of receptors they can 
bind to [10]. However, it has recently become possible to 
suggest that methionine- and leucine-enkephalin bind with 
somewhat different affinities to the different subtypes of 
opiate receptors with leucine-enkephalin being more pro- 
totypical of the delta receptor, and met-enkephalin ex- 
hibiting somewhat more reactivity to the mu site. Neverthe- 
less, both peptides are more delta-like than is beta- 
endorphin, which interacts with mu sites and delta sites with 
great ease [10,27]. 
Adding to the confusion of the relationship between 
methionine- and leucine-enkephalin is the question of the 
biosynthesis of the enkephalins. Relatively little progress has 
been made on specific biosynthesis of the enkephalins of 
central nervous system (in contrast the beta-endorphin). 
However, recent work in adrenal by Lewis and co-workers 
[25] strongly suggests that in, at least, adrenal the enkepha- 
lins come from a 55,000 Dalton precursor which contains 
seven replicates of methionine-enkephalin and one replicate 
of  leucine-enkephalin. Whether this same biosynthetic pat- 
tern will be found in central nervous system and how that 
will relate to the apparent separate distribution of methionine- 
leucine-enkephalin is an open question at this point. 
Most recently another opiate peptide has been discovered 
by Avram Goldstein and co-workers at Stanford [16]. This 
substance, known as dynorphin, was purified from pig pitui- 
tary using a guinea pig ileum bioassay. In analyzing the 
structure of dynorphin it became apparent that dynorphin 
contained the sequence of leucine-enkephalin as its N-ter- 
minus. However, the C terminus of  dynorphin (as far as 
it is known) contains eight amino acids which are unique in 
that they do not appear to occur in any other known opiate or 
non-opiate peptide. This substance would appear to have the 
same type of  relationship to leucine-enkephalin as methi- 
onine-enkephalin does to beta-endorphin. And the 
same types of questions have arisen about it. Where is 
dynorphin? How is it synthesized? What is its relationship to 
the enkephalins, and to other peptides? 
Using immunocytochemical techniques we (in collabora- 
tion with Avram Goldstein and co-workers) [51] have been 
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able to locate dynorphin in the magnocellular neurons of 
hypothalamus (supraoptic nucleus, paraventricular nucleus) 
with fiber projections to the posterior pituitary. For technical 
reasons it has been difficult to demonstrate other dynorphin 
cell bodies and fiber in central nervous system. However, 
extensive blocking studies in brain and pituitary have 
allowed the conclusion that dynorphin is separable from 
leucine-enkephalin in the supraoptic nucleus and posterior 
pituitary. Biochemical studies using HPLC and RIA [14] 
have strongly reinforced the existence of both peptides in 
posterior pituitary [51]. Dynorphin and leu-enkephalin ap- 
pear to have quite different distributions in the posterior 
lobe, with pituitary dynorphin being contained in large 
neurosecretory processes [51]  and endings whereas 
enkephalin is contained within axonal-like fibers in the por- 
tion of the gland near the intermediate lobe [40]. It is, never- 
theless, possible that both opioids arise from the same cells 
of origin (and even possibly the same precursor protein) but 
are stored and transported via different pituitary procedures. 
It is known that vasopressin, oxytocin and neurophysin are 
contained in the same general type of magnocellular neurons 
(cf [56]). However, it is not clear whether dynorphin is in 
these cells or perhaps other magnocellular cells in the same 
general nucleus. 
Thus, with respect to both enkephalin and dynorphin, 
several substantial questions continue to exist. Most critical 
among those is whether they arise from a common cell of 
origin, or share a common biosynthetic route, and whether 
they constitute anatomically and physiologically separate 
systems, with distinct receptor populations. 
Conclus ion  
It can be seen from the above overview that the opioid 
peptide systems have opened up new avenues of thought in 
neuroscience research. The existence of multiple opioid and 
non-opioid peptides within the same cells (beta-endorphin/ 
alpha-MSH/gamma-MSH) is a particularly important phe- 
nomenon since it suggests the possibility that they might act 
in concert to modulate physiology-as indicated by recent 
findings. Furthermore, the possibility that the same cell may 
produce two opioids--methionine- and leucine-enkephalin in 
adrenal and brain or leucine-enkephalin and dynorphin in 
hypothalamus--also raises several interesting questions with 
regard to their combined roles. On the other hand, if these 
related peptides--eg enkephalins and dynorphin---are found 
in separate anatomical pathways and bind to different 
receptors--the redundancy of peptide structure and opiate 
function becomes a question of great import. 
In all cases, the study of endogenous opioids sheds light 
not only on these systems per se, but on more general prin- 
ciples of neurobiology. 
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